<DOC>
	<DOCNO>NCT02920541</DOCNO>
	<brief_summary>The purpose study determine safety profile tolerability S 055746 patient AML , high high risk MDS , term Dose-Limiting Toxicities ( DLTs ) , Maximum Tolerated Dose ( MTD ) determine Recommended Phase 2 Dose ( RP2D ) safety profile ( DLT , MTD ) , PK profile , PD profile preliminary efficacy .</brief_summary>
	<brief_title>Dose-escalation Study Oral Administration S 055746 Patients With Acute Myeloid Leukaemia Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Women men age &gt; = 18 year Patients cytologically confirm document de novo , secondary therapyrelated AML exclude acute promyelocytic leukaemia : relapsed refractory disease &gt; = 65 year previously treat AML , candidate intensive chemotherapy candidate standard chemotherapy Patients cytologically confirm documented MDS non proliferative Chronic Myelomonocytic Leukaemia ( CMML ) relapse refractory previous treatment line include least one hypomethylating agent therapy : high high risk MDS without establish alternative therapy transform AML without establish alternative therapy Ability swallow oral tablet ( ) World Health Organization ( WHO ) performance status 02 Circulating white blood cell &lt; = 30 x 10^9 /L &lt; = 13 x10^9 non proliferative CMML Adequate renal hepatic function Negative serum pregnancy test within 7 day prior first day study drug administration Patients must use effective contraception Written inform consent Foreseeable poor compliance study procedure Legally incapacitate person guardianship trusteeship Pregnant breastfeed woman Participation therapeutic interventional study involve investigational drug intake time within 2 week least 5 halflives patient already enrol Previous treatment BH3 mimetic Patients recover baseline CTCAE &lt; = Grade 1 toxicity due prior therapy receive studied disease Any previous antileukaemic treatment study disease within least 5 halflives 2 week ( hydroxycarbamide permit ) Any radiotherapy within 4 week first intake ( except palliative radiotherapy localize lesion ) Major surgery within 3 week first intake S 055746 Allogenic stem cell transplant within 6 month first intake S 055746 patient still need immunosuppressive treatment Leukaemic leptomeningeal leukaemic central nervous system involvement Concomitant uncontrolled infection , organ dysfunction medical disease likely interfere evaluation S 055746 safety study outcome Human immunodeficiency virus ( HIV ) infection , hepatitis B active hepatitis C infection Within 6 month prior first intake S 055746 , history myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , and/or stenting , ischemic/haemorrhagic stroke , atrial fibrillation , digestive haemorrhagic risk , deep venous/arterial thromboembolic complication bleed diathesis Decreased Left Ventricular Ejection Fraction ( LVEF ) QTcF prolongation Patients receive QT prolong drug Coagulopathies increase risk bleeding complication Other malignancy within 2 year prior first intake Strong moderate CYP3A4 inhibitor inducer ( treatment , food drink product ) within 7 day prior first intake Treatment highly metabolise CYP3A4 CYP2D6 and/or narrow therapeutic index , multienzymes and/or OATP substrates herbal product within 7 day prior first intake . Patients receive proton pump inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>